Hiroko Bando

12PUBLICATIONS
44CO-AUTHORS
Environmental epidemiologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Medical mycologyDisease surveillance
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Sep 24, 2026
An exceptionally late and severe radiation recall dermatitis with chest-wall ulceration 32 years after breast radiotherapy: a case report and literature review.

|Apr 16, 2026
Dynamic changes in serum HER2-peptide-specific autoantibodies predict response to neoadjuvant therapy in HER2-positive breast cancer.

|Mar 19, 2026
Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study.

Norikazu Masuda, Hiroyuki Yasojima, Hiroko Bando

|Feb 05, 2026
Venlafaxine reduces hot flashes in hormone receptor-positive breast cancer patients receiving tamoxifen: a prospective single-arm, open-label trial.

Riko Sato, Rena Kamohara, Tomohei Matsuo

|Sep 02, 2025
Tumor-expressed GPNMB orchestrates Siglec-9+ TAM polarization and EMT to promote metastasis in triple-negative breast cancer.

Thuy Linh Dang Cao, Kunio Kawanishi, Sachie Hashimoto

|Jul 18, 2025
Health-related quality of life and physical activity collected via mobile application and wearable device in patients with HR +/HER2 - advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone: 6-month longitudinal study (JBCRG-26).

Hiroko Bando, Aya Ueda, Kaori Terata

Pageof 2

Frequent Collaborators

4 joint publications

Norikazu Masuda

3 joint publications

Sachie Hashimoto

3 joint publications

Masakazu Toi

3 joint publications

Rikiya Nakamura